Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Volrustomig - AstraZeneca

Next Previous
X
Search
Drug Profile

Volrustomig - AstraZeneca

Alternative Names: MEDI-5752; PD-1/CTLA-4 bispecific mAb; PD-l/CTLA-4 DuetMab

Latest Information Update: 30 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; Daiichi Sankyo Company; MedImmune; Presage Biosciences
  • Class Antineoplastics; Bispecific antibodies; Immunoglobulin Fc fragments; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Adenocarcinoma; Malignant-mesothelioma; Non-small cell lung cancer; Squamous cell cancer
  • Phase II Biliary cancer; Liver cancer; Solid tumours
  • Phase I Renal cell carcinoma; Sarcoma

Most Recent Events

  • 30 Oct 2024 AstraZeneca plans a regulatory submission in Non small cell lung cancer, Malignant mesothelioma, Squamous cell cancer, Cervical cancer in 2025 or beyond (AstraZeneca pipeline, October 2024)
  • 01 Oct 2024 Arcus Biosciences enters in clinical trial collaboration with AstraZeneca to develop casdatifan in combination with volrustomig for Renal cell carcinoma
  • 13 Sep 2024 Efficacy data from the phase II GEMINI trial in Gastric cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top